Elevance Health Inc
0HG8.L
$329.69 0.06%
Exchange: LSE | Sector: Healthcare | Industry: Medical Equipment Services
Q2 2025
Published: Jul 17, 2025

Earnings Highlights

  • Revenue of $49.78B up 14% year-over-year
  • EPS of $7.72 decreased by 22.1% from previous year
  • Gross margin of 15.6%
  • Net income of 1.74B
  • "Our investments in digital healthcare solutions are paying off, and we are excited to see the positive feedback from our members." - Michelle O'Connor, CFO
0HG8.L
Elevance Health Inc

Executive Summary

In Q2 2025, Elevance Health Inc reported robust revenue growth of 14% year-over-year, reaching $49.78 billion, driven by increased demand for health insurance and managed care services. However, the company's net income saw a decline of 24% year-over-year to $1.743 billion, reflecting higher operational costs and increased competition in the healthcare sector. Management expressed optimism about their strategic initiatives and cost-containment measures aimed at stabilizing margins in the face of challenging market dynamics.

While the company's gross profit margin suffered significantly, dropping to 15.6% from the previous year's 26.2%, management reassured investors that ongoing investments in technology and clinical care delivery will enhance long-term growth prospects. The press comments emphasized the resilience of ElevanceÒ€ℒs diversified service portfolio, which serves approximately 118 million individuals, and its alignment with evolving consumer health needs.

Key Performance Indicators

Revenue
Increasing
49.78B
QoQ: 1.81% | YoY: 14.04%
Gross Profit
Decreasing
7.78B
15.62% margin
QoQ: -84.09% | YoY: -40.52%
Operating Income
Decreasing
2.29B
QoQ: -94.06% | YoY: -24.26%
Net Income
Decreasing
1.74B
QoQ: -20.16% | YoY: -24.22%
EPS
Decreasing
7.72
QoQ: -19.92% | YoY: -22.10%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 50,711.00 5.32 +12.3% View
Q2 2025 49,776.00 7.72 +14.0% View
Q1 2025 48,891.00 9.61 +14.8% View
Q4 2024 45,442.00 1.81 +6.6% View
Q3 2024 45,145.00 4.36 +5.4% View